Growth hormone stimulates galactopoiesis in healthy lactating women.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Sixteen normally lactating women underwent a double-blind randomized placebo-controlled trial of recombinant human growth hormone (hGH) to assess the effect of hGH on milk production in early lactation.

Why It Was Studied

No adverse effects were seen with hGH treatment and no major changes noted in milk constituents.

The hGH concentrations in milk were low and did not change with therapy.

Who Took Part

The age groups tagged for this paper are adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Growth Hormone, Hormones, Insulin-Like Growth Factor I, Lactation, Milk, Human and Osmolar Concentration.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1992 (Acta endocrinologica), a journal based in Denmark.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.